Soares Karen sold $22K of CLOV

Soares Karen (Chief Legal Officer) sold 4,681 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.61 on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Soares Karen
Published Jun 16, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CLOV
Neutral
high confidence
Mentioned
$CLOV
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CLOVNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale amount, price, and post-transaction holdings, disclosed as part of a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is unlikely to drive a major repricing without additional fundamental catalysts.

03

What to watch

The article provides only the sale details; it does not indicate whether there were concurrent buys, option exercises, or broader insider activity trends.

Relevance 2/10Novelty 6/10Timing: Filed 2026-06-16; transaction dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Clover Health Investments, Corp./DE.

Company-level read

Ticker impact

$CLOVNeutralHigh confidence
Context

Clover Health’s Chief Legal Officer Karen Soares sold 4,681 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect should be small and short-lived unless paired with other news.

Evidence & confidence

The filing is a standard officer sale with a stated 10b5-1 plan, providing disclosure but no new operating/regulatory/financial information.

Market effects

Minimal; this is company-specific insider transaction disclosure, not a sector-wide signal.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if it clusters with other negative signals.

Key entities

  • Clover Health Investments, Corp./DE

    Subject of the Form 4 insider transaction disclosure.

  • Karen Soares

    Chief Legal Officer who sold shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNHMed

Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments

CMS proposed reforms to combat fraud in Medicare, Medicaid, CHIP, and the Health Insurance Marketplace, aiming to save $90B over 10 years. The rule strengthens oversight, requires self-reporting of overpayments, and increases transparency. Managed care stocks fell, including UNH, HUM, CVS, CLOV, CNC, MOH, ELV, and OSCR. Medicare anti-fraud efforts saved $41.9B in 2025, with a $22.30 return per dollar spent.

$HUMHighAI 9/10

Humana (HUM) Stock Hits New 52-Week High

Humana (HUM) reached a new 52-week high after reporting Q3 2026 earnings with a smaller loss and raised full-year EPS guidance. Competitors like CVS Health and Elevance Health also saw gains. Clover Health (CLOV) reported Q3 2026 earnings with a slight profit and raised full-year targets.

$CLOVHighAI 8/10

Clover Health (CLOV) Q3 2026 Earnings Call Transcript

Clover Health (CLOV) reported Q3 2026 earnings, highlighting 49% YoY membership growth to 157,000 members, 57% revenue increase to $2.3B, and doubled adjusted EBITDA to $97M. The company achieved high Star Ratings for its plans and improved HEDIS quality performance. Clover Assistant's engagement accelerated, driving better care and economics. The board appointed Clay Thornton as permanent CFO. Management expects continued growth and profitability in 2027 and 2028.